Alexander I. Spira, MD, PhD, FACP

All Clinical Trials for Alexander I. Spira, MD, PhD, FACP

Clinical Trial 61186372NSC3004

A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy

Clinical Trial TSC-007

A Phase 2 multi-center open-label basket trial of ABI-009 (nab-sirolimus) for adult and adolescent patients with solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

Clinical Trial TPX-0022-02

A PHASE 1B/2 STUDY OF TPX-0022 IN COMBINATION WITH EQ143 IN NON-SMALL CELL LUNG CANCER SUBJECTS

Clinical Trial TWT-203

PHASE 1b/2 DOSE-CONFIRMING, MULTIPART, MULTICENTER STUDY OF CFI-402257 AS A SINGLE AGENT IN ADVANCED SOLID TUMORS AND IN COMBINATION WITH FULVESTRANT IN PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER AFTER DISEASE PROGRESSION ON PRIOR CDK4/6 AND ENDOCRINE THERAPY

Clinical Trial U31402-A-U301

” A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy”

Clinical Trial Calithera CX-228-301

A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Clinical Trial 516-014

A Multicenter, Open-Label, Extension Study of the Safety and Tolerability of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Patients with Advanced or Metastatic Solid Malignancies

Clinical Trial NAV-1104

Phase 1 Study of SHP2 Inhibitor BBP-398 in Combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation

Clinical Trial JBI-802-101

A First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered JBI-802 in Patients with Advanced Solid Tumors

Clinical Trial FURMO

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations Including Exon 20 Insertion Mutations

Clinical Trial DR-01-ONC-001

A Multicenter, Open-Label, First-in-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Clinical Trial ASP3082

A Phase I Study of ASP3082 in Participants with Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies with KRAS G12D

Clinical Trial SGN-ALPV-001

A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors

Clinical Trial VS-6766-204

A Phase 1/2 Study of VS-6766 in Combination with Adagrasib in Patients with KRAS G12C Mutant Non-Small Cell Lung Cancer

Clinical Trial ALKS 4230-003

Clinical and Immunologic Activity of Nemvaleukin Alfa With a Less Frequent IV Dosing Schedule as Monotherapy and in Combination with Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients (ARTISTRY-3)

Clinical Trial RMC-6291-001

Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRAS G12C Mutant Solid Tumors

Clinical Trial H002-101

A Phase 1/2a, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-Tumor Activity of H002 in Patients with Active Epidermal Growth Factor Receptor Mutation Locally Advanced or Metastatic Non-Small Lung Cancer

Clinical Trial IO-202-CL-002

A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose Expansion Study of IO-202 in Combination with Pembrolizumab in Subjects with Advanced, Relapsed, or Refractory Solid Tumors

Clinical Trial ASN004

An Open Label, Multicenter, Dose-Finding Clinical Phase 1 Study of ASN004 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy with Advanced Malignant Solid Tumors.

Clinical Trial XTX101

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients with Advanced Solid Tumors.

Clinical Trial NUV-868

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination with Olaparib or Enzalutamide in Adult Patients with Advanced Solid Tumors.

Clinical Trial PEEL-224

An Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients with Advanced Solid Tumors.

Clinical Trial ERAS-007-04

A Phase 1b/2 Master Protocol of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Hematologic Malignancies (HERKULES-4).

Clinical Trial AZD8701

A Phase 1 First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination with Durvalumab (MEDI4736) in Participants with Advanced Solid Tumors.

Clinical Trial SPX-101

A Phase 1, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of an Anti-Claudin 18.2 Antibody SPX-101 in Patients with Advanced or Refractory Solid Tumors

Clinical Trial RMC-6236

Phase 1/1b Multicenter Open-Label Study of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Specific Mutations in KRAS.

Clinical Trial BNT142-01

First-in-Human, Open-Label, Mulitcenter, Phase 1/2a, Dose Escalation Trial with Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT142 in Patients with CLDN6-Positive Advanced Solid Tumors.

Clinical Trial XMT-1660

A Phase 1b, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors

Clinical Trial DZ2019E0001

A Phase 1/2, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation

Clinical Trial 21498

A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203)

Clinical Trial 21308

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN‑c3 in Combination with Niraparib in Subjects with Platinum-Resistant Ovarian Cancer

Clinical Trial 21239

A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure

Clinical Trial 20388

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib in Combination with Pembrolizumab in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol I)

Clinical Trial 20386

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation with Brain Metastases (CodeBreak 101 Subprotocol G)

Clinical Trial 20382

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)

Clinical Trial DS1062-A-U104

A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab with or without Platinum Chemotherapy in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04) (Phase 1b Study of Dato-DXd in Combination with Durvalumab with or without Platinum Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer

Clinical Trial D967YC00001

A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+)

Clinical Trial 47MAB-ADVCA-101

A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of STI-6643, an Anti-CD47 Human Monoclonal Antibody, in Subjects with Advanced Solid Tumors

Clinical Trial GO-010

A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer

Clinical Trial ERAS-007-02

Phase 1b/2, Open-Label, Multicenter Study of ERAS-007 in Combination with Other Anti-Cancer Therapies in Patients with Advanced Non-Small-Cell Lung Cancer (HERKULES-2)

Clinical Trial BT7480-100

Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies

Clinical Trial RBS2418

A First-in-Human, Phase 1a/b Dose Escalation and Expansion Study to Evaluate RBS2418 as Monotherapy and in Combination with Pembrolizuamab in Subjects with Advanced Unresectable, Recurrent Metastatic Tumors.

Clinical Trial BBP-398

A Phase 1 Study of the SHP2 Inhibitor BBP-398 in Combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation

Clinical Trial BIO-106

A Phase 1/2 Study of BIO-106 as Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Cancers (Starbridge-1)

Clinical Trial CF33-hNIS

A Phase 1, Dose Escalation, Safety, and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumors

Clinical Trial TNG908-C101

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-Tumor Activity of TNG908 in Patients with MTAP-Deleted Advanced or Metatstatic Solid Tumors.

Clinical Trial PRT2527-01

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT2527 in Patients with Advanced Solid Tumors

Clinical Trial AN4005

An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients with Advanced Tumors

Clinical Trial NUV-422-04

A Phase 1b/2 Safety and Efficacy Study of NUV-422 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical Trial NUV-422-03

Randomized, Non-Comparative Phase 1/2 Study of NUV-422 in Combination with Fulvestrant in Patients with Hormone Receptor-Positive Epidermal Growth Factor Receptor2-Negative (HR+ HER2-) Advanced Breast Cancer

Clinical Trial SET-101

A Phase 1/1b, Open-Label Multi Center Two Part Study of SETD2 Inhibitor EZM414 in Subjects with Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Clinical Trial PY314-1-101

A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Clinical Trial BDTX-1535

A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer

Clinical Trial BLU-451-1

A Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR Exon 20 Insertion Mutations

Clinical Trial INBRX-209

A Randomized, Blinded, Placebo-Controlled, Phase 2 Study of INBRX-109 in Unrsectable or Metastatic Conventional Chondrosarcoma

Clinical Trial CLN-619-001

A Phase 1 Dose Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors

Clinical Trial Onc-392-001

Safety, Pharmacokinetics, and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase 1A/1B Study

Clinical Trial BB1701

A First-in-Human, Open Label, Multiple Dose, Dose Escalation, and Cohort Expansion Phase I Study to Investigate the Safety, Tolerablity, Pharmacokinetics and Antitumor Activity of BB-1701 in Patients with Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Clinical Trial D9077C00001

A Phase 2 Open-Label, Multicenter Randomized Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-Stage (II-IIIA) NSCLC

Clinical Trial CINC280AUS12

A Phase 2 Trial of Neoadjuvant and Adjuvant Capmatinib in Participants with Stages IB-IIIA, N2, and Selected IIIB (T3N2 or T4N2) NSCLC with MET Exon 14 Skipping Mutation or High MET Amplification

Clinical Trial USOR 21320

A Phase 1/2 Open-Label Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutated, Metastatic NSCLC Who Have Progressed After Treatment with Osimertinib

Clinical Trial TTI-621-03

A Phase 1/2 Study of TTI-621 in Combination with Doxorubacin in Patients with Unresectable or Metastatic High-Grade Leiomyosarcoma

Clinical Trial INBRX105

An Open-Label, Multicenter, First-in-Human Dose Escalation, Phase 1 Study of INBRX-105 and INBRX-105 in Combination with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors

Clinical Trial D910GC00001

A Randomized, Double Blind, Placebo-Controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy in Patients with Resectable Gastric and GE Junction Cancer

Clinical Trial HFB-301001-01

A Dose Escalation Study of HFB301001 (OX40 Agonist Antibody) in Adult Patients with Advanced Solid Tumors

Clinical Trial ASP1570

A Phase 1 Study of ASP1570 in Participants with Solid Tumors

Clinical Trial ASP7517

A Phase 1/2, Open-Label Study Investigating the Safety, Tolerability and Efficacy of ASP7517 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Known to Express WT1 Antigen

Clinical Trial PRJ1-3024

A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors

Clinical Trial ES002023-1001

An Open-Label, Mulitcenter, First-in-Human, Dose Escalation, Phase 1 Study of ES002023 in Patients with Locally Advanced or Metastatic Solid Tumors

Clinical Trial IMM2902-101

A Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients with HER2-Expressing Advanced Solid Tumors

Clinical Trial M21-404

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 in Adult Subjects with Advanced Solid Tumors

Clinical Trial ZB131-101

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Cancer-Specific Plectin (CSP)-Targeting Functional Antibody in Solid Tumors That Are Likley to Express CSP

Clinical Trial HFB200301-01

A Phase 1, Open-Label, Multi-Center, Dose Escalation and expansion study of HFB200301 (TNFR2 Agonist Antibody) in Adult Patients with Advanced Solid Tumors

Clinical Trial HBI-2376-101

A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Clinical Trial NVL-520-01

A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and other Solid Tumors

Clinical Trial CTIV1708

A Phase 1/2 Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 when Administered via Intratumoral Injection as a Single Agent and in Combination with Intravenous Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors.

Clinical Trial BGB-A317-A1217-301

A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiation Followed by Ociperlimab Plus Tislelizumab or Tislelizumab Plus CCRT Followed by Tislelizumab Versus CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced, Unresectable NSCLC

Clinical Trial STRO-002-GM2

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers).

Clinical Trial STK-012-101

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors

Clinical Trial M21-410

A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Pembrolizumab or Budigalimab

Clinical Trial RLY-2608-101

A First-in-Human Study of Mutant-Selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer

Clinical Trial RTX-224-01

A Phase 1/2 Study of RTX-224 for the Treatment of Patients with Advanced Solid Tumors.

Clinical Trial 516-010

A Two-Cohort, Two-Part, Phase 1, Multicenter, Open-Label, Fixed-Sequence, Drug-Drug Interaction with QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Tumors.

Clinical Trial BLU-701-1101

A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.

Clinical Trial NBF-006

A Phase 1/1b Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF-006 in Patients with Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients with KRAS-Mutated Non-Small Cell Lung Cancer.

Clinical Trial SALA-002-EW16

A Phase I Trial of LSD1 Inhibitor Seclidemstat (SP-2577) with and without Topetecan and Cyclophosphamide in Patients with Relapsed or Refractory Ewing Sarcoma and Select Sarcomas

Clinical Trial EFT226-0002

A Phase 1/2 Open Label, Sequential Group, Dose Escalation and Cohort Expansion Sutdy Evaluating the Safety, PK, PD and Antitumor Activity of eFT226 in Subjects with Selected Advanced Solid Tumors

Clinical Trial LOXO-RAS-20001

A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutated Advanced Solid Tumors

Clinical Trial MVR-T3011-003

A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered via Intravenous Infusion as a Single Agent and in Combination with Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors

Clinical Trial GO-007

A Screening Study for the Selection of Patients for Clinical Studies Targeting Tumor-Specific Antigens (Non-Interventional)

Clinical Trial VX15-2503-12

A Phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients with Advanced, Recurrent, or Metastatic Squamous Cell Cancer of the Head and Neck

Clinical Trial FW-2020-1

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in combination with nivolumab in adults with advanced solid tumors.

Clinical Trial KZR-261-101

A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects with Advanced Solid Malignancies

Clinical Trial ERAS-007-03

Phase 1b/2 Study of Agents Targeting the Mitogen Activated Protein Kinase Pathway in Patients with Advanced GI Malignancies

Clinical Trial MRG004A-001

“An Open-Label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Assess
the Safety, Tolerability, Anti-Tumor Activity and Pharmacokinetics of MRG004A in
Patients with Tissue Factor Positive Advanced or Metastatic Solid Tumors”

Clinical Trial AVB500-PC-005

A Phase 1b/2 Randomized Study of AVB-S6-500 plus Nabpaclitaxel
and Gemcitabine in Patients with Locally Advanced
or Metastatic Pancreatic Adenocarcinoma

Clinical Trial C4401001

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE
SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS,
AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED
OR METASTATIC TUMORS

Clinical Trial 20291

A Phase 1b/2,  Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects with Advanced Solid Tumors with KRAS G12C Mutation                                         **MANY SUBPROTOCOLS FOR THIS TRIAL**

Clinical Trial 20289

A Phase I Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies

Clinical Trial 20305

An Open-Label, Phase 1b, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Efficacy of the Aryl Hydocarbon Receptor Inhibitor (AhRi) BAY 2416964 in Combination with Pembrolizumab in Participants with Advanced Tumors

Clinical Trial 18020

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Clinical Trial TWT-101

A First in Human, Phase 1/2 Study of CFI-402411, Hematopoeitic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advnanced Solid Malignancies

Clinical Trial TTX-030-002

A Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination with Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors

Clinical Trial TPX-0022-01

A Phase I, Open-Label, Multicenter, First in Human Study of the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of TPX-0022, A Novel MET/CSF1R/SRC Inhibitor, in Patients with Advanced Solid Tumors Harboring Genetic Alterations I MET

Clinical Trial RTX-24-01

Open-Label, Multicenter, First in Human Phase 1/2 Study of RTX-240 for the Treatment of Patients with Relapsed/Refractory or Locally Advanced Solid Tumors

Clinical Trial DF6002-001

A Phase 1/2, First in Human, Multi-Part, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors

Clinical Trial TPX-0046-01

A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects with Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations

Clinical Trial ORIC-101-18101

An Open-Label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors

Clinical Trial M19-037

A Phase I, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors

Clinical Trial NB-ND021 (NM21-1480)-101

Phase 1/2 Study of NM21-1480 (Anti-PD-L1/Anti-4-1BB/Anti-HAS Tri-Specific Antibody) in Adults with Advanced Solid Tumors

Clinical Trial JAB-3312-1003

A Phase 1/2a, Multi-center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB3312 in Combination with Pembrolizumab or Binimetinib in Adults with Advanced Solid Tumors

Clinical Trial I-MAB

A Phase I Study of TJ210001 Administered in Subjects with Relapsed or Refractory Advanced Solid Tumors

Clinical Trial CPO-100-US-101

A Phase I, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO-100 in Adults with Advanced Solid Tumors

Clinical Trial D976MC00001

A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Unresectable and or Mets Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology

Clinical Trial 20383

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib in Combination with Everolimus in Subjects with Advanced Solid Tumors with KRAS G12C Mutation

Clinical Trial KN 8701

A Phase 1/1b Open-Label, Multicenter, Two-Part Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-8701 in Subjects with BRAF Mutation Positive Solid Tumors

Clinical Trial TCTLR-101

Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study of Transcon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

Clinical Trial D6185C00001

An Open-Label, Multi-Drug, Biomarker-Directed, Multicenter Phase II Umbrella Study in Patients with NSCLC, Who Progressed on and Anti-PD-1/PD-L1 Containing Therapy

Clinical Trial BGB-A317-A1217-302

A Phase III, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination with Tislelizumab Compared to Pembrolizumab in Patients with Previously Untreated, PD-L1 Selected, and Locally Advanced, Unresectable or Metastatic NSCLC

Clinical Trial D910MC00001

Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy.

Clinical Trial 20139

A Phase III, Randomized, Controlled, Multi-Center, 3 Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus SOC Chemo Alone for the Treatment of Patients with EGFR Positive, Resectable NSCLC

Clinical Trial D910LC00001

A Phase III, Randomized, Multicenter, Double Blind, Placebo Controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-Based Chemotherapy in Completely Resected Stage II-III NSCLC

Clinical Trial ACT16146

Randomized, Open-Label Phase II Study of SAR408701 Combined with Pembrolizumab and Pembrolizumab Alone in Patients with CEACAM5 and PD-L1 Positive Advanced/Metastatic Non-Squamous NSCLC.

Clinical Trial 20270

Phase II Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced NSCLC with KRAS G12C Mutation

Clinical Trial 20384

A Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG510 (pINN Sotorasib) in Combination with Carboplatin and Pemetrexed; with Docetaxel; or with Carboplatin and Paclitaxel in Subjects with Advanced NSCLC with KRAS G12C Mutation

Clinical Trial U31402-A-U103

A Phase I Open-Label Study of Patritumab Deruxtecan (U3-1402) in Combination with Osimertinib in Subjects with Locally Advanced or Mets EGFR-Mutated NSCLC

Clinical Trial 61186372EDI1001

Phase I, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced NSCLC

Clinical Trial KL 264-01

A Phase I-II, First in Human Study of SKB264 in Patients with Locally Advanced Unresectable and Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies

Clinical Trial 20414

An Open-Label Phase 1b/2 Study of Surufatinib in Combination with Tislelizumab in Subjects with Advanced Solid Tumors

Clinical Trial MRTX849-001

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C

Clinical Trial PCS6422G1-01

A Phase 1b Dose-Escalation Study of the Safety and Pharmacokinetics of Fixed-Dose PCS6422 with Escalating Doses of Capecitabine Administered Orally to Patients with Advanced, Refractory Gastrointestinal Tract Tumors

Clinical Trial 20310

A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS G12C

Clinical Trial 21194

A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib in Combination with MVASI and FOLFIRI and in Combination with MVASI and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS G12C Mutation

Clinical Trial DS1062-A-U301

Phase 3 Randomized Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Clinical Trial 20344

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

Clinical Trial 20331

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial 18194

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolRá) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Clinical Trial CLN-081-001

A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Clinical Trial ZWI-ZW49-101

Clinical Trial 73841937NSC1001

An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Clinical Trial 20137

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION (SKYSCRAPER-03)

Clinical Trial M19-611

A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects with PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

Clinical Trial APG-115-US-002

Clinical Trial KL26401

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable /Metastatic Solid Tumors who are refractory to Available Standard Therapies

Clinical Trial 19043

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors (IMMU-132-11)

Clinical Trial TPX-005-001

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Clinical Trial ASTX295-01

Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors

Clinical Trial 849-001

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Clinical Trial 101-18101

An Open-label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors

Clinical Trial GO-005

A Phase 1/2 Study of GRT-C903/GRT-R904, a Vaccine Targeting Shared Neoantigens, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors

Clinical Trial M14-239

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Clinical Trial C2321001

A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Clinical Trial LOXO-RET-17001

A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001

Clinical Trial Janssen 61186372EDI10051

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer

Clinical Trial GO-003

An Observational Feasibility Study for the Production of a Patient-Specific Neoantigen Cancer Vaccine in Patients with Advanced Cancer

Clinical Trial 17-167

A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Clinical Trial 18-020

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Clinical Trial Astex ASTX029

Study of ASTX029 in Subjects With Advanced Solid Tumors

Clinical Trial STRO-001-BCM1

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Clinical Trial DS1062-A-J101

First-in-human Study of DS-1062a for Advanced Solid Tumors

Clinical Trial Tesaro 4020-01-001

A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Clinical Trial R3767-ONC-1613

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Clinical Trial M14-237

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors